We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unlocking Q2 Potential of 10x Genomics (TXG): Exploring Wall Street Estimates for Key Metrics
Read MoreHide Full Article
In its upcoming report, 10x Genomics (TXG - Free Report) is predicted by Wall Street analysts to post quarterly loss of $0.47 per share, reflecting an increase of 11.3% compared to the same period last year. Revenues are forecasted to be $150.9 million, representing a year-over-year increase of 2.8%.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Bearing this in mind, let's now explore the average estimates of specific 10x Genomics metrics that are commonly monitored and projected by Wall Street analysts.
The average prediction of analysts places 'Revenues- Consumables' at $119.63 million. The estimate indicates a change of +6.3% from the prior-year quarter.
Analysts predict that the 'Revenues- Services' will reach $5.51 million. The estimate indicates a year-over-year change of +63.2%.
Analysts' assessment points toward 'Revenues- Instruments' reaching $26.28 million. The estimate indicates a year-over-year change of -15.1%.
Over the past month, shares of 10x Genomics have returned +3.4% versus the Zacks S&P 500 composite's -5.9% change. Currently, TXG carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Unlocking Q2 Potential of 10x Genomics (TXG): Exploring Wall Street Estimates for Key Metrics
In its upcoming report, 10x Genomics (TXG - Free Report) is predicted by Wall Street analysts to post quarterly loss of $0.47 per share, reflecting an increase of 11.3% compared to the same period last year. Revenues are forecasted to be $150.9 million, representing a year-over-year increase of 2.8%.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Bearing this in mind, let's now explore the average estimates of specific 10x Genomics metrics that are commonly monitored and projected by Wall Street analysts.
The average prediction of analysts places 'Revenues- Consumables' at $119.63 million. The estimate indicates a change of +6.3% from the prior-year quarter.
Analysts predict that the 'Revenues- Services' will reach $5.51 million. The estimate indicates a year-over-year change of +63.2%.
Analysts' assessment points toward 'Revenues- Instruments' reaching $26.28 million. The estimate indicates a year-over-year change of -15.1%.
View all Key Company Metrics for 10x Genomics here>>>
Over the past month, shares of 10x Genomics have returned +3.4% versus the Zacks S&P 500 composite's -5.9% change. Currently, TXG carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>